Search

Your search keyword '"Nagane, Motoo"' showing total 489 results
Start Over Author "Nagane, Motoo"
489 results on '"Nagane, Motoo"'

1. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults.

Author

Weller, Michael, Le Rhun, Emilie, Van den Bent, Martin, Chang, Susan M, Cloughesy, Timothy F, Goldbrunner, Roland, Hong, Yong-Kil, Jalali, Rakesh, Jenkinson, Michael D, Minniti, Giuseppe, Nagane, Motoo, Razis, Evangelia, Roth, Patrick, Rudà, Roberta, Tabatabai, Ghazaleh, Wen, Patrick Y, Short, Susan C, and Preusser, Matthias

Subjects
Humans, Lymphoma, Central Nervous System Neoplasms, Brain Neoplasms, Combined Modality Therapy, Quality of Life, Adult, adverse affects, dose, interruptions, prevention, reexposure, toxicity, Patient Safety, Neurosciences, Brain Disorders, Rare Diseases, Clinical Trials and Supportive Activities, Brain Cancer, Cancer, Clinical Research, 7.3 Management and decision making, Management of diseases and conditions, 7.1 Individual care needs, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here, the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose, and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy, and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions, and reexposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.

Published
2023

3. Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

Author

Fukuoka, Kohei, Kurihara, Jun, Shofuda, Tomoko, Kagawa, Naoki, Yamasaki, Kai, Ando, Ryo, Ishida, Joji, Kanamori, Masayuki, Kawamura, Atsufumi, Park, Young-Soo, Kiyotani, Chikako, Akai, Takuya, Keino, Dai, Miyairi, Yosuke, Sasaki, Atsushi, Hirato, Junko, Inoue, Takeshi, Nakazawa, Atsuko, Koh, Katsuyoshi, Nishikawa, Ryo, Date, Isao, Nagane, Motoo, Ichimura, Koichi, and Kanemura, Yonehiro

Published
2023
Full Text
View/download PDF

4. Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumors

Author

Takami, Hirokazu, Satomi, Kaishi, Fukuoka, Kohei, Nakamura, Taishi, Tanaka, Shota, Mukasa, Akitake, Saito, Nobuhito, Suzuki, Tomonari, Yanagisawa, Takaaki, Sugiyama, Kazuhiko, Kanamori, Masayuki, Kumabe, Toshihiro, Tominaga, Teiji, Tamura, Kaoru, Maehara, Taketoshi, Nonaka, Masahiro, Asai, Akio, Yokogami, Kiyotaka, Takeshima, Hideo, Iuchi, Toshihiko, Kobayashi, Keiichi, Yoshimoto, Koji, Sakai, Keiichi, Nakazato, Yoichi, Matsutani, Masao, Nagane, Motoo, Nishikawa, Ryo, and Ichimura, Koichi

Published
2023
Full Text
View/download PDF

5. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)

Author

Barajas, Ramon F, Politi, Letterio S, Anzalone, Nicoletta, Schöder, Heiko, Fox, Christopher P, Boxerman, Jerrold L, Kaufmann, Timothy J, Quarles, C Chad, Ellingson, Benjamin M, Auer, Dorothee, Andronesi, Ovidiu C, Ferreri, Andres JM, Mrugala, Maciej M, Grommes, Christian, Neuwelt, Edward A, Ambady, Prakash, Rubenstein, James L, Illerhaus, Gerald, Nagane, Motoo, Batchelor, Tracy T, and Hu, Leland S

Subjects
Clinical Research, Cancer, Rare Diseases, Patient Safety, Biomedical Imaging, Lymphoma, Neurosciences, Hematology, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Central Nervous System, Central Nervous System Neoplasms, Consensus, Humans, Magnetic Resonance Imaging, Positron-Emission Tomography, Reproducibility of Results, imaging, MRI, PCNSL, PET, primary central nervous system lymphoma, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, and response assessment. Institutional imaging variation and inconsistent clinical trial reporting diminishes the reliability and reproducibility of clinical response assessment. In this context, we aimed to: (1) critically review the use of advanced positron emission tomography (PET) and magnetic resonance imaging (MRI) in the setting of PCNSL; (2) provide results from an international survey of clinical sites describing the current practices for routine and advanced imaging, and (3) provide biologically based recommendations from the International PCNSL Collaborative Group (IPCG) on adaptation of standardized imaging practices. The IPCG provides PET and MRI consensus recommendations built upon previous recommendations for standardized brain tumor imaging protocols (BTIP) in primary and metastatic disease. A biologically integrated approach is provided to addresses the unique challenges associated with the imaging assessment of PCNSL. Detailed imaging parameters facilitate the adoption of these recommendations by researchers and clinicians. To enhance clinical feasibility, we have developed both "ideal" and "minimum standard" protocols at 3T and 1.5T MR systems that will facilitate widespread adoption.

Published
2021

6. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.

Author

Arita, Hideyuki, Matsushita, Yuko, Machida, Ryunosuke, Yamasaki, Kai, Hata, Nobuhiro, Ohno, Makoto, Yamaguchi, Shigeru, Sasayama, Takashi, Tanaka, Shota, Higuchi, Fumi, Iuchi, Toshihiko, Saito, Kuniaki, Kanamori, Masayuki, Matsuda, Ken-Ichiro, Miyake, Yohei, Tamura, Kaoru, Tamai, Sho, Nakamura, Taishi, Uda, Takehiro, Okita, Yoshiko, Fukai, Junya, Sakamoto, Daisuke, Hattori, Yasuhiko, Pareira, Eriel, Hatae, Ryusuke, Ishi, Yukitomo, Miyakita, Yasuji, Tanaka, Kazuhiro, Takayanagi, Shunsaku, Otani, Ryohei, Sakaida, Tsukasa, Kobayashi, Keiichi, Saito, Ryuta, Kurozumi, Kazuhiko, Shofuda, Tomoko, Nonaka, Masahiro, Suzuki, Hiroyoshi, Shibuya, Makoto, Komori, Takashi, Sasaki, Hikaru, Mizoguchi, Masahiro, Kishima, Haruhiko, Nakada, Mitsutoshi, Sonoda, Yukihiko, Tominaga, Teiji, Nagane, Motoo, Nishikawa, Ryo, Kanemura, Yonehiro, Kuchiba, Aya, Narita, Yoshitaka, and Ichimura, Koichi

Subjects
1p/19q codeletion, CDKN2A, Glioma, IDH1/2, TERT, Adolescent, Adult, Aged, Aged, 80 and over, Astrocytoma, Brain Neoplasms, Chromosome Deletion, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, Female, Glioblastoma, Glioma, Humans, Isocitrate Dehydrogenase, Karnofsky Performance Status, Male, Middle Aged, Multivariate Analysis, Mutation, Neoplasm Grading, Neurosurgical Procedures, Oligodendroglioma, Prognosis, Promoter Regions, Genetic, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Survival Rate, Telomerase, Young Adult
Abstract

TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these mutations have an impact on patient survival independent of 1p/19q codeletion is unknown. In this study, we investigated the impact of TERT promoter mutations on survival in IDH-mutated glioma cases. Detailed clinical information and molecular status data were collected for a cohort of 560 adult patients with IDH-mutated gliomas. Among these patients, 279 had both TERT promoter mutation and 1p/19q codeletion, while 30 had either TERT promoter mutation (n = 24) or 1p/19q codeletion (n = 6) alone. A univariable Cox proportional hazard analysis for survival using clinical and genetic factors indicated that a Karnofsky performance status score (KPS) of 90 or 100, WHO grade II or III, TERT promoter mutation, 1p/19q codeletion, radiation therapy, and extent of resection (90-100%) were associated with favorable prognosis (p

Published
2020

7. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study

Author

Aoki, Tomokazu, Kagawa, Naoki, Sugiyama, Kazuhiko, Wakabayashi, Toshihiko, Arakawa, Yoshiki, Yamaguchi, Shigeru, Tanaka, Shota, Ishikawa, Eiichi, Muragaki, Yoshihiro, Nagane, Motoo, Nakada, Mitsutoshi, Suehiro, Satoshi, Hata, Nobuhiro, Kuroda, Junichiro, Narita, Yoshitaka, Sonoda, Yukihiko, Iwadate, Yasuo, Natsumeda, Manabu, Nakazato, Yoichi, Minami, Hironobu, Hirata, Yuki, Hagihara, Shunsuke, and Nishikawa, Ryo

Published
2021
Full Text
View/download PDF

9. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

Author

Fujimoto, Kenji, Arita, Hideyuki, Satomi, Kaishi, Yamasaki, Kai, Matsushita, Yuko, Nakamura, Taishi, Miyakita, Yasuji, Umehara, Toru, Kobayashi, Keiichi, Tamura, Kaoru, Tanaka, Shota, Higuchi, Fumi, Okita, Yoshiko, Kanemura, Yonehiro, Fukai, Junya, Sakamoto, Daisuke, Uda, Takehiro, Machida, Ryunosuke, Kuchiba, Aya, Maehara, Taketoshi, Nagane, Motoo, Nishikawa, Ryo, Suzuki, Hiroyoshi, Shibuya, Makoto, Komori, Takashi, Narita, Yoshitaka, and Ichimura, Koichi

Published
2021
Full Text
View/download PDF

11. Epstein–Barr virus‐positive monoclonal lymphoplasmacytic proliferation associated with neurosyphilis in an immunocompetent patient: A case report.

Author

Hibiya, Takashi, Nagahama, Kiyotaka, Matsumoto, Yoshie, Saito, Kuniaki, Sasaki, Nobuyoshi, Kobayashi, Keiichi, Otsu, Akiyasu, Shimasaki, Teppei, Takeuchi, Kengo, Shiokawa, Yoshiaki, Nagane, Motoo, and Shibahara, Junji

Subjects
NEUROSYPHILIS, SPIROCHETES, MAGNETIC resonance imaging, TREPONEMA pallidum, CENTRAL nervous system
Abstract

Syphilis is an infectious disease caused by the spirochete bacterium Treponema pallidum. Neurosyphilis results from the infection of the nervous system with Treponema pallidum, which can occur at any stage of syphilis. Neurosyphilis is often overlooked because of its rarity. Early‐stage neurosyphilis with brain mass formation is rare. We present a case of early‐stage neurosyphilis with prominent Epstein–Barr virus (EBV)‐positive monoclonal lymphoplasmacytic proliferation in an immunocompetent patient. A 36‐year‐old man presented with a chief complaint of a progressively worsening headache, a newly developed skin rash, and a fever. Magnetic resonance imaging showed a mass lesion, which measured 18 mm in diameter, in the left frontal lobe of the cerebrum. The patient underwent an emergency operation to remove the abscess. A pathological investigation revealed complex findings. There was an abscess in the cerebrum. Lymphoplasmacytic meningitis was also noted. In addition, a vaguely nodular lesion, which was composed of plasmacytoid and lymphoid cells, was observed around the abscess. Immunohistochemically, an anti‐Treponema pallidum antibody revealed numerous Treponemas around the abscess. In situ hybridization revealed that the plasmacytoid and lymphoid cells were Epstein–Barr encoding region (EBER)‐positive; κ‐positive cells were significantly more prevalent than λ‐positive cells, suggesting light‐chain restriction. Postoperatively, parenteral antibiotics were administered for four weeks. The patient has been free of recurrence for two years since the surgery. No association between neurosyphilis and EBV‐positive lymphoplasmacytic proliferation has ever been reported. Mass formation in early‐stage neurosyphilis is an exceptionally rare event. The present case indicates that in syphilis patients, lymphoproliferative disorders that lead to mass formation may be caused by concomitant EBV reactivation. Furthermore, when treating patients with mass lesions of the central nervous system, it is important to check their medical history and perform laboratory screening for infectious diseases to avoid overlooking syphilis infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, Okazaki, Shogo, Ohmura, Mitsuyo, Ishikawa, Miyuki, Sampetrean, Oltea, Onishi, Nobuyuki, Wakimoto, Hiroaki, Yoshikawa, Momoko, Seishima, Ryo, Iwasaki, Yoshimi, Morikawa, Takayuki, Abe, Shinya, Takao, Ayumi, Shimizu, Misato, Masuko, Takashi, Nagane, Motoo, Furnari, Frank B, Akiyama, Tetsu, Suematsu, Makoto, Baba, Eishi, Akashi, Koichi, Saya, Hideyuki, and Nagano, Osamu

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Brain Cancer, Prevention, Biotechnology, Rare Diseases, Cancer, Brain Disorders, Neurosciences, Aetiology, 2.1 Biological and endogenous factors, Amino Acid Transport System y+, Animals, Antioxidants, Apoptosis, Brain Neoplasms, Cell Membrane, Cell Movement, Cell Proliferation, Cystine, ErbB Receptors, Gene Expression Regulation, Neoplastic, Glioma, Glutamic Acid, Humans, Mice, Mice, Inbred NOD, Mice, Nude, Mice, SCID, Reactive Oxygen Species, Sulfasalazine, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Extracellular free amino acids contribute to the interaction between a tumor and its microenvironment through effects on cellular metabolism and malignant behavior. System xc(-) is composed of xCT and CD98hc subunits and functions as a plasma membrane antiporter for the uptake of extracellular cystine in exchange for intracellular glutamate. Here, we show that the EGFR interacts with xCT and thereby promotes its cell surface expression and function in human glioma cells. EGFR-expressing glioma cells manifested both enhanced antioxidant capacity as a result of increased cystine uptake, as well as increased glutamate, which promotes matrix invasion. Imaging mass spectrometry also revealed that brain tumors formed in mice by human glioma cells stably overexpressing EGFR contained higher levels of reduced glutathione compared with those formed by parental cells. Targeted inhibition of xCT suppressed the EGFR-dependent enhancement of antioxidant capacity in glioma cells, as well as tumor growth and invasiveness. Our findings establish a new functional role for EGFR in promoting the malignant potential of glioma cells through interaction with xCT at the cell surface. Cancer Res; 76(10); 2954-63. ©2016 AACR.

Published
2016

14. 10221-ML-11 A CASE OF PRIMARY CENTRAL NERVOUS SYSTEM ADULT T CELL LEUKEMIA

Author

Seiya, Yosuke, primary, Sasaki, Nobuyoshi, additional, Kobayashi, Makoto, additional, Hidaka, Rei, additional, Saito, Kuniaki, additional, Hibiya, Takashi, additional, Yamagishi, Yuki, additional, Ikeda, Kensuke, additional, Kobayashi, Keiichi, additional, Komori, Takashi, additional, Nakatomi, Hirofumi, additional, Takayama, Nobuyuki, additional, Shibahara, Junji, additional, and Nagane, Motoo, additional

Published
2023
Full Text
View/download PDF

18. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis

Author

Feng, Haizhong, Lopez, Giselle Y, Kim, Chung Kwon, Alvarez, Angel, Duncan, Christopher G, Nishikawa, Ryo, Nagane, Motoo, Su, An-Jey A, Auron, Philip E, Hedberg, Matthew L, Wang, Lin, Raizer, Jeffery J, Kessler, John A, Parsa, Andrew T, Gao, Wei-Qiang, Kim, Sung-Hak, Minata, Mutsuko, Nakano, Ichiro, Grandis, Jennifer R, McLendon, Roger E, Bigner, Darell D, Lin, Hui-Kuan, Furnari, Frank B, Cavenee, Webster K, Hu, Bo, Yan, Hai, and Cheng, Shi-Yuan

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Rare Diseases, Cancer, 2.1 Biological and endogenous factors, Aetiology, Brain Neoplasms, Carcinogenesis, Cells, Cultured, ErbB Receptors, Glioma, Head and Neck Neoplasms, Humans, Membrane Proteins, Phosphorylation, Proto-Oncogene Proteins c-akt, Signal Transduction, TNF Receptor-Associated Factor 6, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated tumorigenesis. In multiple cancer cell lines, EGFR activated phosphorylation of tyrosine 750 (Y750) of DCBLD2, which is located within a recently identified binding motif for TNF receptor-associated factor 6 (TRAF6). Consequently, phosphorylation of DCBLD2 Y750 recruited TRAF6, leading to increased TRAF6 E3 ubiquitin ligase activity and subsequent activation of AKT, thereby enhancing EGFR-driven tumorigenesis. Moreover, evaluation of patient samples of gliomas and HNCs revealed an association among EGFR activation, DCBLD2 phosphorylation, and poor prognoses. Together, our findings uncover a pathway in which DCBLD2 functions as a signal relay for oncogenic EGFR signaling to promote tumorigenesis and suggest DCBLD2 and TRAF6 as potential therapeutic targets for human cancers that are associated with EGFR activation.

Published
2014

19. Karnofsky Performance Status and Quality of Life in Patients with Relapsed or Refractory Primary CNS Lymphoma from a Phase I/II Study of Tirabrutinib

Author

Arakawa, Yoshiki, primary, Narita, Yoshitaka, additional, Nagane, Motoo, additional, Mishima, Kazuhiko, additional, Terui, Yasuhito, additional, Yonezawa, Hajime, additional, Asai, Katsunori, additional, Fukuhara, Noriko, additional, Sugiyama, Kazuhiko, additional, Shinojima, Naoki, additional, Aoi, Arata, additional, and Nishikawa, Ryo, additional

Published
2023
Full Text
View/download PDF

20. The role of nonlinear dimension reduction of genome‐wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH‐wildtype

Author

Satomi, Kaishi, primary, Saito, Kuniaki, additional, Shimoyamada, Hiroaki, additional, Onizuka, Hiromi, additional, Shibayama, Takahiro, additional, Hibiya, Takashi, additional, Hayashi, Akimasa, additional, Nagahama, Kiyotaka, additional, Yamagishi, Yuki, additional, Sasaki, Nobuyoshi, additional, Kobayashi, Keiichi, additional, Gomyo, Miho, additional, Nagane, Motoo, additional, and Shibahara, Junji, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Figures and Legends from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

Author

Nejo, Takahide, primary, Matsushita, Hirokazu, primary, Karasaki, Takahiro, primary, Nomura, Masashi, primary, Saito, Kuniaki, primary, Tanaka, Shota, primary, Takayanagi, Shunsaku, primary, Hana, Taijun, primary, Takahashi, Satoshi, primary, Kitagawa, Yosuke, primary, Koike, Tsukasa, primary, Kobayashi, Yukari, primary, Nagae, Genta, primary, Yamamoto, Shogo, primary, Ueda, Hiroki, primary, Tatsuno, Kenji, primary, Narita, Yoshitaka, primary, Nagane, Motoo, primary, Ueki, Keisuke, primary, Nishikawa, Ryo, primary, Aburatani, Hiroyuki, primary, Mukasa, Akitake, primary, Saito, Nobuhito, primary, and Kakimi, Kazuhiro, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

Author

Nejo, Takahide, primary, Matsushita, Hirokazu, primary, Karasaki, Takahiro, primary, Nomura, Masashi, primary, Saito, Kuniaki, primary, Tanaka, Shota, primary, Takayanagi, Shunsaku, primary, Hana, Taijun, primary, Takahashi, Satoshi, primary, Kitagawa, Yosuke, primary, Koike, Tsukasa, primary, Kobayashi, Yukari, primary, Nagae, Genta, primary, Yamamoto, Shogo, primary, Ueda, Hiroki, primary, Tatsuno, Kenji, primary, Narita, Yoshitaka, primary, Nagane, Motoo, primary, Ueki, Keisuke, primary, Nishikawa, Ryo, primary, Aburatani, Hiroyuki, primary, Mukasa, Akitake, primary, Saito, Nobuhito, primary, and Kakimi, Kazuhiro, primary

Published
2023
Full Text
View/download PDF

25. Data from Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma

Author

Nejo, Takahide, primary, Matsushita, Hirokazu, primary, Karasaki, Takahiro, primary, Nomura, Masashi, primary, Saito, Kuniaki, primary, Tanaka, Shota, primary, Takayanagi, Shunsaku, primary, Hana, Taijun, primary, Takahashi, Satoshi, primary, Kitagawa, Yosuke, primary, Koike, Tsukasa, primary, Kobayashi, Yukari, primary, Nagae, Genta, primary, Yamamoto, Shogo, primary, Ueda, Hiroki, primary, Tatsuno, Kenji, primary, Narita, Yoshitaka, primary, Nagane, Motoo, primary, Ueki, Keisuke, primary, Nishikawa, Ryo, primary, Aburatani, Hiroyuki, primary, Mukasa, Akitake, primary, Saito, Nobuhito, primary, and Kakimi, Kazuhiro, primary

Published
2023
Full Text
View/download PDF

28. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

Author

Wakabayashi, Toshihiko, Natsume, Atsushi, Mizusawa, Junki, Katayama, Hiroshi, Fukuda, Haruhiko, Sumi, Minako, Nishikawa, Ryo, Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Ito, Tamio, Beppu, Takaaki, Nakamura, Hideo, Kayama, Takamasa, Sato, Shinya, Nagane, Motoo, Mishima, Kazuhiko, Nakasu, Yoko, Kurisu, Kaoru, Yamasaki, Fumiyuki, Sugiyama, Kazuhiko, Onishi, Takanori, Iwadate, Yasuo, Terasaki, Mizuhiko, Kobayashi, Hiroyuki, Matsumura, Akira, Ishikawa, Eiichi, Sasaki, Hikaru, Mukasa, Akitake, Matsuo, Takayuki, Hirano, Hirofumi, Kumabe, Toshihiro, Shinoura, Nobusada, Hashimoto, Naoya, Aoki, Tomokazu, Asai, Akio, Abe, Tatsuya, Yoshino, Atsuo, Arakawa, Yoshiki, Asano, Kenichiro, Yoshimoto, Koji, Shibui, Soichiro, and Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)

Published
2018
Full Text
View/download PDF

29. Supplementary Table from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Author

Tateishi, Kensuke, primary, Miyake, Yohei, primary, Kawazu, Masahito, primary, Sasaki, Nobuyoshi, primary, Nakamura, Taishi, primary, Sasame, Jo, primary, Yoshii, Yukie, primary, Ueno, Toshihide, primary, Miyake, Akio, primary, Watanabe, Jun, primary, Matsushita, Yuko, primary, Shiba, Norio, primary, Udaka, Naoko, primary, Ohki, Kentaro, primary, Fink, Alexandria L., primary, Tummala, Shilpa S., primary, Natsumeda, Manabu, primary, Ikegaya, Naoki, primary, Nishi, Mayuko, primary, Ohtake, Makoto, primary, Miyazaki, Ryohei, primary, Suenaga, Jun, primary, Murata, Hidetoshi, primary, Aoki, Ichio, primary, Miller, Julie J., primary, Fujii, Yukihiko, primary, Ryo, Akihide, primary, Yamanaka, Shoji, primary, Mano, Hiroyuki, primary, Cahill, Daniel P., primary, Wakimoto, Hiroaki, primary, Chi, Andrew S., primary, Batchelor, Tracy T., primary, Nagane, Motoo, primary, Ichimura, Koichi, primary, and Yamamoto, Tetsuya, primary

Published
2023
Full Text
View/download PDF

30. Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Author

Tateishi, Kensuke, primary, Miyake, Yohei, primary, Kawazu, Masahito, primary, Sasaki, Nobuyoshi, primary, Nakamura, Taishi, primary, Sasame, Jo, primary, Yoshii, Yukie, primary, Ueno, Toshihide, primary, Miyake, Akio, primary, Watanabe, Jun, primary, Matsushita, Yuko, primary, Shiba, Norio, primary, Udaka, Naoko, primary, Ohki, Kentaro, primary, Fink, Alexandria L., primary, Tummala, Shilpa S., primary, Natsumeda, Manabu, primary, Ikegaya, Naoki, primary, Nishi, Mayuko, primary, Ohtake, Makoto, primary, Miyazaki, Ryohei, primary, Suenaga, Jun, primary, Murata, Hidetoshi, primary, Aoki, Ichio, primary, Miller, Julie J., primary, Fujii, Yukihiko, primary, Ryo, Akihide, primary, Yamanaka, Shoji, primary, Mano, Hiroyuki, primary, Cahill, Daniel P., primary, Wakimoto, Hiroaki, primary, Chi, Andrew S., primary, Batchelor, Tracy T., primary, Nagane, Motoo, primary, Ichimura, Koichi, primary, and Yamamoto, Tetsuya, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Author

Tateishi, Kensuke, primary, Miyake, Yohei, primary, Kawazu, Masahito, primary, Sasaki, Nobuyoshi, primary, Nakamura, Taishi, primary, Sasame, Jo, primary, Yoshii, Yukie, primary, Ueno, Toshihide, primary, Miyake, Akio, primary, Watanabe, Jun, primary, Matsushita, Yuko, primary, Shiba, Norio, primary, Udaka, Naoko, primary, Ohki, Kentaro, primary, Fink, Alexandria L., primary, Tummala, Shilpa S., primary, Natsumeda, Manabu, primary, Ikegaya, Naoki, primary, Nishi, Mayuko, primary, Ohtake, Makoto, primary, Miyazaki, Ryohei, primary, Suenaga, Jun, primary, Murata, Hidetoshi, primary, Aoki, Ichio, primary, Miller, Julie J., primary, Fujii, Yukihiko, primary, Ryo, Akihide, primary, Yamanaka, Shoji, primary, Mano, Hiroyuki, primary, Cahill, Daniel P., primary, Wakimoto, Hiroaki, primary, Chi, Andrew S., primary, Batchelor, Tracy T., primary, Nagane, Motoo, primary, Ichimura, Koichi, primary, and Yamamoto, Tetsuya, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma

Author

Tateishi, Kensuke, primary, Miyake, Yohei, primary, Kawazu, Masahito, primary, Sasaki, Nobuyoshi, primary, Nakamura, Taishi, primary, Sasame, Jo, primary, Yoshii, Yukie, primary, Ueno, Toshihide, primary, Miyake, Akio, primary, Watanabe, Jun, primary, Matsushita, Yuko, primary, Shiba, Norio, primary, Udaka, Naoko, primary, Ohki, Kentaro, primary, Fink, Alexandria L., primary, Tummala, Shilpa S., primary, Natsumeda, Manabu, primary, Ikegaya, Naoki, primary, Nishi, Mayuko, primary, Ohtake, Makoto, primary, Miyazaki, Ryohei, primary, Suenaga, Jun, primary, Murata, Hidetoshi, primary, Aoki, Ichio, primary, Miller, Julie J., primary, Fujii, Yukihiko, primary, Ryo, Akihide, primary, Yamanaka, Shoji, primary, Mano, Hiroyuki, primary, Cahill, Daniel P., primary, Wakimoto, Hiroaki, primary, Chi, Andrew S., primary, Batchelor, Tracy T., primary, Nagane, Motoo, primary, Ichimura, Koichi, primary, and Yamamoto, Tetsuya, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, primary, Okazaki, Shogo, primary, Ohmura, Mitsuyo, primary, Ishikawa, Miyuki, primary, Sampetrean, Oltea, primary, Onishi, Nobuyuki, primary, Wakimoto, Hiroaki, primary, Yoshikawa, Momoko, primary, Seishima, Ryo, primary, Iwasaki, Yoshimi, primary, Morikawa, Takayuki, primary, Abe, Shinya, primary, Takao, Ayumi, primary, Shimizu, Misato, primary, Masuko, Takashi, primary, Nagane, Motoo, primary, Furnari, Frank B., primary, Akiyama, Tetsu, primary, Suematsu, Makoto, primary, Baba, Eishi, primary, Akashi, Koichi, primary, Saya, Hideyuki, primary, and Nagano, Osamu, primary

Published
2023
Full Text
View/download PDF

34. Data from The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, primary, Okazaki, Shogo, primary, Ohmura, Mitsuyo, primary, Ishikawa, Miyuki, primary, Sampetrean, Oltea, primary, Onishi, Nobuyuki, primary, Wakimoto, Hiroaki, primary, Yoshikawa, Momoko, primary, Seishima, Ryo, primary, Iwasaki, Yoshimi, primary, Morikawa, Takayuki, primary, Abe, Shinya, primary, Takao, Ayumi, primary, Shimizu, Misato, primary, Masuko, Takashi, primary, Nagane, Motoo, primary, Furnari, Frank B., primary, Akiyama, Tetsu, primary, Suematsu, Makoto, primary, Baba, Eishi, primary, Akashi, Koichi, primary, Saya, Hideyuki, primary, and Nagano, Osamu, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 2 from The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, primary, Okazaki, Shogo, primary, Ohmura, Mitsuyo, primary, Ishikawa, Miyuki, primary, Sampetrean, Oltea, primary, Onishi, Nobuyuki, primary, Wakimoto, Hiroaki, primary, Yoshikawa, Momoko, primary, Seishima, Ryo, primary, Iwasaki, Yoshimi, primary, Morikawa, Takayuki, primary, Abe, Shinya, primary, Takao, Ayumi, primary, Shimizu, Misato, primary, Masuko, Takashi, primary, Nagane, Motoo, primary, Furnari, Frank B., primary, Akiyama, Tetsu, primary, Suematsu, Makoto, primary, Baba, Eishi, primary, Akashi, Koichi, primary, Saya, Hideyuki, primary, and Nagano, Osamu, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Information from The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, primary, Okazaki, Shogo, primary, Ohmura, Mitsuyo, primary, Ishikawa, Miyuki, primary, Sampetrean, Oltea, primary, Onishi, Nobuyuki, primary, Wakimoto, Hiroaki, primary, Yoshikawa, Momoko, primary, Seishima, Ryo, primary, Iwasaki, Yoshimi, primary, Morikawa, Takayuki, primary, Abe, Shinya, primary, Takao, Ayumi, primary, Shimizu, Misato, primary, Masuko, Takashi, primary, Nagane, Motoo, primary, Furnari, Frank B., primary, Akiyama, Tetsu, primary, Suematsu, Makoto, primary, Baba, Eishi, primary, Akashi, Koichi, primary, Saya, Hideyuki, primary, and Nagano, Osamu, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 3 from The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(—)

Author

Tsuchihashi, Kenji, primary, Okazaki, Shogo, primary, Ohmura, Mitsuyo, primary, Ishikawa, Miyuki, primary, Sampetrean, Oltea, primary, Onishi, Nobuyuki, primary, Wakimoto, Hiroaki, primary, Yoshikawa, Momoko, primary, Seishima, Ryo, primary, Iwasaki, Yoshimi, primary, Morikawa, Takayuki, primary, Abe, Shinya, primary, Takao, Ayumi, primary, Shimizu, Misato, primary, Masuko, Takashi, primary, Nagane, Motoo, primary, Furnari, Frank B., primary, Akiyama, Tetsu, primary, Suematsu, Makoto, primary, Baba, Eishi, primary, Akashi, Koichi, primary, Saya, Hideyuki, primary, and Nagano, Osamu, primary

Published
2023
Full Text
View/download PDF

39. Publisher Correction: DNA demethylation is associated with malignant progression of lower-grade gliomas

Author

Nomura, Masashi, Saito, Kuniaki, Aihara, Koki, Nagae, Genta, Yamamoto, Shogo, Tatsuno, Kenji, Ueda, Hiroki, Fukuda, Shiro, Umeda, Takayoshi, Tanaka, Shota, Takayanagi, Shunsaku, Otani, Ryohei, Nejo, Takahide, Hana, Taijun, Takahashi, Satoshi, Kitagawa, Yosuke, Omata, Mayu, Higuchi, Fumi, Nakamura, Taishi, Muragaki, Yoshihiro, Narita, Yoshitaka, Nagane, Motoo, Nishikawa, Ryo, Ueki, Keisuke, Saito, Nobuhito, Aburatani, Hiroyuki, and Mukasa, Akitake

Published
2019
Full Text
View/download PDF

40. DNA demethylation is associated with malignant progression of lower-grade gliomas

Author

Nomura, Masashi, Saito, Kuniaki, Aihara, Koki, Nagae, Genta, Yamamoto, Shogo, Tatsuno, Kenji, Ueda, Hiroki, Fukuda, Shiro, Umeda, Takayoshi, Tanaka, Shota, Takayanagi, Shunsaku, Otani, Ryohei, Nejo, Takahide, Hana, Taijun, Takahashi, Satoshi, Kitagawa, Yosuke, Omata, Mayu, Higuchi, Fumi, Nakamura, Taishi, Muragaki, Yoshihiro, Narita, Yoshitaka, Nagane, Motoo, Nishikawa, Ryo, Ueki, Keisuke, Saito, Nobuhito, Aburatani, Hiroyuki, and Mukasa, Akitake

Published
2019
Full Text
View/download PDF

41. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors

Author

Fukuoka, Kohei, Kanemura, Yonehiro, Shofuda, Tomoko, Fukushima, Shintaro, Yamashita, Satoshi, Narushima, Daichi, Kato, Mamoru, Honda-Kitahara, Mai, Ichikawa, Hitoshi, Kohno, Takashi, Sasaki, Atsushi, Hirato, Junko, Hirose, Takanori, Komori, Takashi, Satomi, Kaishi, Yoshida, Akihiko, Yamasaki, Kai, Nakano, Yoshiko, Takada, Ai, Nakamura, Taishi, Takami, Hirokazu, Matsushita, Yuko, Suzuki, Tomonari, Nakamura, Hideo, Makino, Keishi, Sonoda, Yukihiko, Saito, Ryuta, Tominaga, Teiji, Matsusaka, Yasuhiro, Kobayashi, Keiichi, Nagane, Motoo, Furuta, Takuya, Nakada, Mitsutoshi, Narita, Yoshitaka, Hirose, Yuichi, Ohba, Shigeo, Wada, Akira, Shimizu, Katsuyoshi, Kurozumi, Kazuhiko, Date, Isao, Fukai, Junya, Miyairi, Yousuke, Kagawa, Naoki, Kawamura, Atsufumi, Yoshida, Makiko, Nishida, Namiko, Wataya, Takafumi, Yamaoka, Masayoshi, Tsuyuguchi, Naohiro, Uda, Takehiro, Takahashi, Mayu, Nakano, Yoshiteru, Akai, Takuya, Izumoto, Shuichi, Nonaka, Masahiro, Yoshifuji, Kazuhisa, Kodama, Yoshinori, Mano, Masayuki, Ozawa, Tatsuya, Ramaswamy, Vijay, Taylor, Michael D., Ushijima, Toshikazu, Shibui, Soichiro, Yamasaki, Mami, Arai, Hajime, Sakamoto, Hiroaki, Nishikawa, Ryo, Ichimura, Koichi, and on behalf of the Japan Pediatric Molecular Neuro-Oncology Group (JPMNG)

Published
2018
Full Text
View/download PDF

45. ACT-19 A REPORT OF PHASE I PART OF PHASE I/II STUDY OF MAINTENANCE THERAPY WITH METFORMIN AND TEMOZOLOMIDE FOR GLIOBLASTOMA

Author

Ohno, Makoto, primary, Kitanaka, Chifumi, additional, Miyakita, Yasuji, additional, Tanaka, Shota, additional, Takahashi, Masamichi, additional, Yanagisawa, Shunsuke, additional, Sonoda, Yukihiko, additional, Matsuda, Kenichiro, additional, Mishima, Kazuhiko, additional, Suzuki, Tomonari, additional, Shirahara, Mitsuaki, additional, Ishikawa, Eiichi, additional, Ohashi, Ken, additional, Nagane, Motoo, additional, and Narita, Yoshitaka, additional

Published
2022
Full Text
View/download PDF

46. GEN-13 PAIRED MUTATIONAL ANALYSIS IN SECONDARY NERVOUS SYSTEM LYMPHOMA AND PCNSL SYSTEMIC RELAPSE REVEALS DRIVER MUTATION CANDIDATES IN THE CENTRAL NERVOUS SYSTEM

Author

Sasaki, Nobuyoshi, primary, Kume, Satoshi, additional, Tateishi, Kensuke, additional, Nakamura, Taishi, additional, Ibayashi, Kenji, additional, Yamagishi, Yuki, additional, Saito, Kuniaki, additional, Kobayashi, Keiichi, additional, Matsushita, Yuko, additional, Hibiya, Yuko, additional, Kitahara, Mai, additional, Suzuki, Saki, additional, Nagano, Reiko, additional, Yamashita, Satoshi, additional, Nakatomi, Hirofumi, additional, Shiokawa, Yoshiaki, additional, Ichimura, Koichi, additional, and Nagane, Motoo, additional

Published
2022
Full Text
View/download PDF

48. Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study

Author

Nagane, Motoo, primary, Ichimura, Koichi, additional, Onuki, Ritsuko, additional, Narushima, Daichi, additional, Honda-Kitahara, Mai, additional, Satomi, Kaishi, additional, Tomiyama, Arata, additional, Arai, Yasuhito, additional, Shibata, Tatsuhiro, additional, Narita, Yoshitaka, additional, Uzuka, Takeo, additional, Nakamura, Hideo, additional, Nakada, Mitsutoshi, additional, Arakawa, Yoshiki, additional, Ohnishi, Takanori, additional, Mukasa, Akitake, additional, Tanaka, Shota, additional, Wakabayashi, Toshihiko, additional, Aoki, Tomokazu, additional, Aoki, Shigeki, additional, Shibui, Soichiro, additional, Matsutani, Masao, additional, Ishizawa, Keisuke, additional, Yokoo, Hideaki, additional, Suzuki, Hiroyoshi, additional, Morita, Satoshi, additional, Kato, Mamoru, additional, and Nishikawa, Ryo, additional

Published
2022
Full Text
View/download PDF

49. Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114C

Author

Mishima, Kazuhiko, primary, Nishikawa, Ryo, additional, Narita, Yoshitaka, additional, Mizusawa, Junki, additional, Sumi, Minako, additional, Koga, Tomoyuki, additional, Sasaki, Nobuyoshi, additional, Kinoshita, Manabu, additional, Nagane, Motoo, additional, Arakawa, Yoshiki, additional, Yoshimoto, Koji, additional, Shibahara, Ichiyo, additional, Shinojima, Naoki, additional, Asano, Kenichiro, additional, Tsurubuchi, Takao, additional, Sasaki, Hikaru, additional, Asai, Akio, additional, Sasayama, Takashi, additional, Momii, Yasutomo, additional, Sasaki, Atsushi, additional, Nakamura, Shigeo, additional, Kojima, Masaru, additional, Tamaru, Jun-ichi, additional, Tsuchiya, Kazuhiro, additional, Gomyo, Miho, additional, Abe, Kayoko, additional, Natsumeda, Manabu, additional, Yamasaki, Fumiyuki, additional, Katayama, Hiroshi, additional, and Fukuda, Haruhiko, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results